| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 47.6 | 1.9 |
| Net income | -190.1 | -306.2 |
| EPS (diluted, $ a share) | $-1.37 | $-2.55 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +2356.5% |
|---|---|
| Operating margin | -351.3% |
10-Q filed with the SEC, NASDAQ: CYTK. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Cytokinetics Inc: key numbers
- Share price
- $51.65Close, Nov 17
- Market cap
- $7.2B
- Shares outstanding
- 139.3MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Cytokinetics Inc
All →Cytokinetics Insider B. Lynne Parshall Sells $274K of Stock
B. Lynne Parshall sold 5,000 shares of Cytokinetics Inc at $54.17 to $55.26 a share (average $54.73) in 2 transactions, worth $274K in total on Nov 9, 2026. Shares held after the trade: 5,784 (-30.6%).
- Value
- $274K
- Shares
- 5,000
- Average price
- $54.73
- Holding change
- -30.6%
- Trade date
- Nov 9, 2026
Cytokinetics Financial Results
Cytokinetics reported Q3 2026 financial results, highlighted by $44.5 million in net product revenue from MYQORZO (aficamten). The company ended the quarter with approximately $1.6 billion in cash and plans to submit a supplemental NDA for aficamten in non-obstructive HCM in Q4 2026.
- Term
- Q3 2026
“Our third quarter results demonstrate continued strong execution as Cytokinetics enters its next phase of growth as a global specialty cardiology biopharmaceutical company.”
Robert I. Blum, Cytokinetics’ President and Chief Executive Officer
“In the U.S., the launch of MYQORZO continued to build solid momentum and increased velocity with growing adoption across a broadening base of prescribers.”
Robert I. Blum, Cytokinetics’ President and Chief Executive Officer
Cytokinetics EVP Research & Development Fady Ibraham Malik Sells $220K of Stock
Fady Ibraham Malik, EVP Research & Development, sold 3,500 shares of Cytokinetics Inc at $62.93 a share, worth $220K in total on Nov 3, 2026. Shares held after the trade: 153,902 (-2.2%).
- Value
- $220K
- Shares
- 3,500
- Price
- $62.93
- Role
- EVP Research & Development
- Holding change
- -2.2%
- Trade date
- Nov 3, 2026
Cytokinetics President & CEO Robert I. Blum Sells $471K of Stock
Robert I. Blum, President & CEO, sold 7,500 shares of Cytokinetics Inc at $62.81 a share, worth $471K in total on Nov 2, 2026. Shares held after the trade: 278,544 (-2.6%).
- Value
- $471K
- Shares
- 7,500
- Price
- $62.81
- Role
- President & CEO
- Holding change
- -2.6%
- Trade date
- Nov 2, 2026
Cytokinetics EVP Research & Development Fady Ibraham Malik Sells $224K of Stock
Fady Ibraham Malik, EVP Research & Development, sold 3,500 shares of Cytokinetics Inc at $64.01 a share, worth $224K in total on Oct 20, 2026. Shares held after the trade: 153,902 (-2.2%).
- Value
- $224K
- Shares
- 3,500
- Price
- $64.01
- Role
- EVP Research & Development
- Holding change
- -2.2%
- Trade date
- Oct 20, 2026
Cytokinetics President & CEO Robert I. Blum Sells $472K of Stock
Robert I. Blum, President & CEO, sold 7,500 shares of Cytokinetics Inc at $62.88 a share, worth $472K in total on Oct 12, 2026. Shares held after the trade: 278,544 (-2.6%).
- Value
- $472K
- Shares
- 7,500
- Price
- $62.88
- Role
- President & CEO
- Holding change
- -2.6%
- Trade date
- Oct 12, 2026